James M. Mock Sells 705 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) CFO James M. Mock sold 705 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the sale, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Moderna Price Performance

Shares of MRNA stock opened at $107.14 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The firm’s 50-day moving average is $99.55 and its two-hundred day moving average is $93.42. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $163.24. The company has a market capitalization of $41.02 billion, a PE ratio of -8.63 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same period in the previous year, the firm earned $3.61 earnings per share. Moderna’s quarterly revenue was down 44.9% compared to the same quarter last year. Analysts predict that Moderna, Inc. will post -7.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on MRNA shares. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday. Canaccord Genuity Group lifted their target price on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a research report on Tuesday, January 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday, March 28th. Finally, HSBC reissued a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $126.49.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently made changes to their positions in the stock. ICA Group Wealth Management LLC acquired a new position in Moderna during the fourth quarter worth $27,000. First Pacific Financial acquired a new position in Moderna during the 3rd quarter worth about $27,000. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna during the 4th quarter valued at about $27,000. Stonebridge Capital Advisors LLC grew its position in Moderna by 79.1% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after acquiring an additional 125 shares in the last quarter. Finally, Arlington Trust Co LLC grew its position in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.